Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions-Reference-Cited by-同舟云学术

Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions

Published:2017-06 Issue: Volume:57 Page:36-49
ISSN:0305-7372
Container-title:Cancer Treatment Reviews
language:en
Short-container-title:Cancer Treatment Reviews

Author:

Hassel Jessica C.,Heinzerling Lucie,Aberle Jens,Bähr Oliver,Eigentler Thomas K.,Grimm Marc-Oliver,Grünwald Victor,Leipe Jan,Reinmuth Niels,Tietze Julia K.,Trojan Jörg,Zimmer Lisa,Gutzmer Ralf

Funder

Bristol-Myers Squibb

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Reference127 articles.

1. Improved survival with ipilimumab in patients with metastatic melanoma;Hodi;N Engl J Med,2010

2. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma;Robert;N Engl J Med,2011

3. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial;Weber;Lancet Oncol,2015

4. Nivolumab in previously untreated melanoma without BRAF mutation;Robert;N Engl J Med,2015

5. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial;Robert;The Lancet,2014

Cited by 261 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Notfälle in der Medikamentösen Tumortherapie;TumorDiagnostik & Therapie;2024-09

2. Notfälle in der Medikamentösen Tumortherapie;Onkologische Welt;2024-07

3. Evolving Precision First-Line Systemic Treatment for Patients with Unresectable Non-Small Cell Lung Cancer;Cancers;2024-06-26

4. Case report: A rare case of anti-PD-1 sintilimab-induced agranulocytosis/severe neutropenia in non-small cell lung cancer and literature review;Frontiers in Oncology;2024-06-18

5. Optimizing immune checkpoint blockade in metastatic uveal melanoma: exploring the association of overall survival and the occurrence of adverse events;Frontiers in Immunology;2024-06-10